4331 studies found for:    "Leukemia"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Unknown  Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Myeloproliferative Disorders;   Acute Lymphocytic Leukemia;   Acute Promyelocytic Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   Chronic Myelomonocytic Leukemia;   Juvenile Myelomonocytic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide
2 Completed Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   High-risk Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Advanced Myelofibrosis
Intervention: Drug: TH-302
3 Unknown  Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia
Conditions: Leukemias;   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Adult T Cell Leukemia (ATL);   Chronic Myeloid Leukemia (CML-BP);   Chronic Lymphocytic Leukemia (CLL);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML)
Intervention: Drug: Terameprocol (EM-1421)
4 Recruiting Red Cell Transfusion Goals in Patients With Acute Leukemias
Conditions: Acute Lymphoblastic Leukemia;   Acute Lymphocytic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Acute Promyelocytic Leukemia (APL)
Interventions: Procedure: Restrictive Transfusion threshold;   Procedure: Standard transfusion threshold
5 Active, not recruiting PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Leukemia;   Leukemia, Lymphocytyc;   CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Intervention: Drug: PCI 32765
6 Active, not recruiting Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphocytic Leukemia;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia
Interventions: Drug: bortezomib;   Drug: belinostat;   Other: laboratory biomarker analysis;   Genetic: western blotting;   Other: pharmacological study;   Other: flow cytometry
7 Terminated A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
Conditions: Leukemia, Lymphoblastic, Acute, T-cell;   Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MK0752, (Notch Inhibitor)
8 Recruiting Dose Escalation Study of EPZ-5676 in Pediatric Patients With Leukemias Bearing a Rearrangement of the MLL Gene
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Acute Leukemias
Intervention: Drug: EPZ-5676
9 Active, not recruiting PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: Clofarabine
10 Active, not recruiting Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
11 Completed
Has Results
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Relapsed Leukemia
Interventions: Drug: clofarabine;   Drug: Etoposide;   Drug: Cyclophosphamide
12 Completed Investigation of Clofarabine in Acute Leukemias
Conditions: Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia
Intervention: Drug: clofarabine
13 Completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Acute Leukemias of Ambiguous Lineage;   Acute Myeloid Leukemia/Transient Myeloproliferative Disorder;   Acute Undifferentiated Leukemia;   Aggressive NK-cell Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Myeloid/NK-cell Acute Leukemia;   Noncutaneous Extranodal Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
14 Suspended Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Conditions: Hairy Cell Leukemia (HCL);   Chronic Lymphocytic Leukemia (CLL);   Non-Hodgkins Lymphoma (NHL);   Cutaneous T Cell Lymphoma (CTCL);   Adult T Cell Lymphoma (ATL)
Intervention:
15 Recruiting Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Conditions: Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Lymphoblastic Lymphoma;   Diffuse Large B-cell Lymphoma;   Burkitt Lymphoma/Leukemia
Interventions: Drug: Clofarabine;   Drug: Mitoxantrone
16 Active, not recruiting Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)
Conditions: B-cell Chronic Lymphocytic Leukemia;   Hematopoietic/Lymphoid Cancer;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Drug: carfilzomib;   Other: Cytokine Assessment;   Other: Pharmacodynamic Studies;   Other: Proteosome Inhibition Assessment;   Other: Pharmacogenomic Studies
17 Active, not recruiting Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
18 Terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Small Intestine Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: obatoclax mesylate;   Drug: liposomal vincristine sulfate;   Other: pharmacological study;   Other: laboratory biomarker analysis
19 Completed MK0457 in Patients With Leukemia (0457-003)(COMPLETED)
Conditions: Chronic Myelogenous Leukemia in Blast Crisis;   Lymphocytic Leukemia, B Cell, Acute;   Myelodysplastic Syndromes;   Myelogenous Leukemia, Chronic
Intervention: Drug: MK0457
20 Terminated A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Leukemia, Lymphocytic, Chronic
Intervention: Drug: Motexafin gadolinium

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years